Lisa DeFazio-Eli
Overview
Explore the profile of Lisa DeFazio-Eli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chumsri S, Weidler J, Ali S, Balasubramanian S, Wallweber G, DeFazio-Eli L, et al.
J Natl Compr Canc Netw
. 2015 Sep;
13(9):1066-70.
PMID: 26358791
In the current genomic era, increasing evidence demonstrates that approximately 2% of HER2-negative breast cancers, by current standard testings, harbor activating mutations of ERBB2. However, whether patients with HER2-negative breast...
2.
Garrett J, Sutton C, Kurupi R, Bialucha C, Ettenberg S, Collins S, et al.
Cancer Res
. 2013 Aug;
73(19):6013-23.
PMID: 23918797
We examined the effects of LJM716, an HER3 (ERBB3) neutralizing antibody that inhibits ligand-induced and ligand-independent HER3 dimerization, as a single agent and in combination with BYL719, an ATP competitive...
3.
DeFazio-Eli L, Strommen K, Dao-Pick T, Parry G, Goodman L, Winslow J
Breast Cancer Res
. 2011 Apr;
13(2):R44.
PMID: 21496232
Introduction: Ligand-bound and phosphorylated ErbB/HER heterodimers are potent signaling forms of this receptor family, and quantitative measurements of these active receptors may be predictive of patient response to targeted therapies....
4.
Larson J, Goodman L, Tan Y, DeFazio-Eli L, Paquet A, Cook J, et al.
Patholog Res Int
. 2010 Dec;
2010:814176.
PMID: 21151530
We report here the results of the analytical validation of assays that measure HER2 total protein (H2T) and HER2 homodimer (H2D) expression in Formalin Fixed Paraffin Embedded (FFPE) breast cancer...
5.
Shi Y, Huang W, Tan Y, Jin X, Dua R, Penuel E, et al.
Diagn Mol Pathol
. 2009 Feb;
18(1):11-21.
PMID: 19214113
The availability of drugs targeting the EGFR/HER/erbB signaling pathway has created a need for diagnostics that accurately predict treatment responses. We have developed and characterized a novel assay to provide...